BIOMAT Database Logo BIOMAT Database Logo

Variations in L-dopa absorption. Report of a parkinsonian patient with high plasma dopa concentration after therapeutical L-dopa dose. 1974

A K Granerus, and R Jagenburg, and S Rödjer, and A Svanborg

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D010649 Phenylalanine An essential aromatic amino acid that is a precursor of MELANIN; DOPAMINE; noradrenalin (NOREPINEPHRINE), and THYROXINE. Endorphenyl,L-Phenylalanine,Phenylalanine, L-Isomer,L-Isomer Phenylalanine,Phenylalanine, L Isomer
D002250 Carbon Radioisotopes Unstable isotopes of carbon that decay or disintegrate emitting radiation. C atoms with atomic weights 10, 11, and 14-16 are radioactive carbon isotopes. Radioisotopes, Carbon
D003653 Decarboxylation The removal of a carboxyl group, usually in the form of carbon dioxide, from a chemical compound. Decarboxylations
D004295 Dihydroxyphenylalanine A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific. Dopa,3,4-Dihydroxyphenylalanine,3-Hydroxy-DL-tyrosine,Dihydroxyphenylalanine Hydrochloride, (2:1),beta-Hydroxytyrosine,3 Hydroxy DL tyrosine,3,4 Dihydroxyphenylalanine,beta Hydroxytyrosine
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine

Related Publications

A K Granerus, and R Jagenburg, and S Rödjer, and A Svanborg
L-dopa malabsorption in a parkinsonian patient with Strongyloides stercoralis duodenitis.
February 1994, Clinical neuropharmacology,
A K Granerus, and R Jagenburg, and S Rödjer, and A Svanborg
A case of L-dopa-responsive parkinsonian syndrome after low-dose oral methotrexate intake.
January 2004, Clinical neuropharmacology,
A K Granerus, and R Jagenburg, and S Rödjer, and A Svanborg
[Treatment with L-dopa in Parkinsonian syndromes].
January 1970, Sistema nervoso,
A K Granerus, and R Jagenburg, and S Rödjer, and A Svanborg
L-dopa induced "serotonin syndrome" in a parkinsonian patient on bromocriptine.
June 1986, Journal of clinical psychopharmacology,
A K Granerus, and R Jagenburg, and S Rödjer, and A Svanborg
[Treatment of parkinsonian states with L-dopa].
November 1971, Bulletin de l'Academie nationale de medecine,
A K Granerus, and R Jagenburg, and S Rödjer, and A Svanborg
Cortical motor overactivation in parkinsonian patients with L-dopa-induced peak-dose dyskinesia.
March 1998, Brain : a journal of neurology,
A K Granerus, and R Jagenburg, and S Rödjer, and A Svanborg
[L-dopa therapy in Parkinsonian syndromes].
September 1970, Il Policlinico. Sezione pratica,
A K Granerus, and R Jagenburg, and S Rödjer, and A Svanborg
[High dose L-dopa infusion during general anesthesia for gastrectomy in a patient with parkinsonism].
January 2002, Masui. The Japanese journal of anesthesiology,
A K Granerus, and R Jagenburg, and S Rödjer, and A Svanborg
Improved high-performance liquid chromatographic analysis with double detection system for L-dopa, its metabolites and carbidopa in plasma of parkinsonian patients under L-dopa therapy.
December 1988, Journal of chromatography,
A K Granerus, and R Jagenburg, and S Rödjer, and A Svanborg
Correlation of clinical symptoms, HVA and 5-HIAA in csf and plasma L-DOPA in Parkinsonian patients treated with L-DOPA and L-DOPA + RO 4-4602.
April 1977, European journal of clinical pharmacology,
Copied contents to your clipboard!